Coherus BioSciences (CHRS) Misses Q3 EPS by 1c, Misses on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.05 +2.94%
Revenue Growth %: +37.8%
Financial Fact:
Net sales: 481.26M
Today's EPS Names:
ORPB, PBCO, SICP, More
Revenue Growth %: +37.8%
Financial Fact:
Net sales: 481.26M
Today's EPS Names:
ORPB, PBCO, SICP, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q3 EPS of ($0.33), $0.01 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $11.6 million versus the consensus estimate of $13.36 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- SLM (SLM) Misses Q3 EPS by 36c; lowers guidance
- FVCBankcorp, Inc. (FVCB) Misses Q3 EPS by 2c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
